Table I.
Serum component | Referenced range | House keeping control | Sampling week | Vehicle control | Silymarin | Low LPE | Middle LPE | High LPE |
---|---|---|---|---|---|---|---|---|
GOT (IU/l) | 69–191 | 141.23±20.5 | 1 | 69.83±8.35a,b | 80.62±7.29a,b | 48.36±5.63b | 77.45±14.5a,b | 87.46±16.73a |
3 | 4298.09±546.27a | 3982.85±504.79a | 1620.58±578.42b | 962.56±512.04b | 1879.40±585.41b | |||
6 | 2099.56±361.43a | 2169.08±358.68a | 821.94±297.18b | 402.82±56.31b | 1168.6±389.25b | |||
GPT (IU/l) | 26–120 | 28.09±4.19 | 1 | 43.83±9.67b | 39.85±2.88b | 33.09±4.79b | 46.09±3.96b | 86.92±19.22a |
3 | 1455.51±402.45a | 1247.49±383.78a,b | 586.89±336.78a,b | 312.25±291.82b | 303.90±185.50b | |||
6 | 2569.26±492.33a,b | 3214.47±527.85a | 1514.42±484.47b,c | 928.39±232.72c | 1620.00±433.67b,c | |||
T-chol (mg/dl) | 63–174 | 55.86±4.72 | 1 | 124.58±11.05 | 114.62±5.40 | 102.55±9.77 | 101.27±9.86 | 106.38±8.39 |
3 | 78.09±5.78a,b | 83.19±9.81b | 88.55±9.69a | 71.42±6.73a,b | 93.77±11.25a,b | |||
6 | 112.28±9.11 | 102.14±8.02 | 116.67±9.44 | 111.42±8.26 | 92.93±8.88 | |||
TG (mg/dl) | 26–145 | 23.86±4.82 | 1 | 26.33±2.91c | 28.62±2.68b,c | 32.27±2.57b,c | 54.36±5.66a | 38.85±4.23b |
3 | 17.16±1.91a,b | 19.20±2.33b | 32.27±3.63a | 22.33±1.88a | 21.15±3.94a | |||
6 | 32.26±7.09 | 27.64±4.00 | 45.61±11.50 | 37.85±4.32 | 27.33±6.99 | |||
T-p (g/ml) | 4.3–6.4 | 4.07±0.42 | 1 | 4.93±0.31b | 5.88±0.26a | 4.31±0.26b | 4.83±0.22b | 4.90±0.27b |
3 | 3.83±0.29c | 3.97±0.37b,c | 5.19±0.4a | 5.02±0.45a,b | 5.90±0.45a | |||
6 | 5.56±0.42a,b | 5.32±0.28a,b | 5.51±0.30a,b | 6.20±0.32a | 4.64±0.22b | |||
Albumin (g/dl) | 2.5–4.8 | 1.95±0.19 | 1 | 2.73±0.16a,b | 2.99±0.11a | 2.45±0.15b | 2.73±0.17a,b | 2.75±0.18a,b |
3 | 2.04±0.18b | 2.14±0.19b | 2.84±0.24a | 2.69±0.26a,b | 3.01±0.26a | |||
6 | 2.83±0.20b,c | 2.68±0.15b,c | 3.07±0.16a,b | 3.34±0.18a | 2.52±0.10c | |||
Globulin (g/dl) | 0.6 | 2.12±0.24 | 1 | 2.23±0.18b | 2.89±0.19a | 1.85±0.15b | 2.17±0.17b | 2.15±0.17b |
3 | 1.79±0.12b | 1.82±0.19b | 2.36±0.18a,b | 2.49±0.26a | 2.89±0.26a | |||
6 | 2.73±0.23a | 2.64±0.16a,b | 2.44±0.16a,b | 2.86±0.23a | 2.12±0.13b | |||
T-bili (mg/dl) | 0.3–0.9 | 0.29±0.02 | 1 | 0.77±0.04 | 0.81±0.04 | 0.70±0.04 | 0.77±0.05 | 0.80±0.04 |
3 | 0.79±0.09 | 0.66±0.06 | 0.94±0.09 | 0.80±0.08 | 0.76±0.08 | |||
6 | 0.30±0.02b | 0.32±0.02a,b | 0.29±0.01b | 0.36±0.02a | 0.29±0.01b | |||
Mean body weight (g) | – | 37.57±1.02 | 40.34±0.98 | 37.16±1.70 | 36.83±0.97 | 37.83±1.03 | 40.28±0.68 | |
Liver weight (g) | – | 2.11±0.07 | 2.42±0.11 | 2.23±0.12 | 2.19±0.11 | 2.23±0.08 | 2.29±0.11 | |
Relative liver weight | – | 5.62±0.08 | 5.99±0.27 | 6.01±0.35 | 5.97±0.24 | 5.92±0.18 | 5.67±0.31 |
Data are presented as mean ± standard deviation (n=8).
Represent comparisons within the same row, where different superscripts indicate significant differences at P<0.05. Referenced ranges of all serum biochemical components listed refer to Clinical chemistry of the laboratory mouse in The Mouse in Biomedical Research. The treatment groups were mice injected with CCl4 twice weekly and subjected to daily gavage-feeding of H2O (vehicle control), silymarin (200 mg/kg BW), a low (20 mg/kg BW), middle (100 mg/kg BW) or high dose (200 mg/kg BW) of LPE. The normal control group mice were not injected with CCl4. Serum samples were collected and analyzed at 1, 3 and 6 weeks. Body and liver weight were measured on the date of euthanasia and relative liver weight was calculated as the proportion of liver weight to body weight. LPE, litchi pericarp extract; CCl4, carbon tetrachloride; BW, body weight; GOT, glutamic oxaloacetate transaminase; GPT, glutamic pyruvic transaminase; TG, triglycerides; T-chol, total cholesterol; T-p, total protein; T-bili, total bilirubin.